Advertisement
(Logo: http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO)
The AWARE (Angiogenesis in Women with Angina pectoris who are notcandidates for Revascularization) study, a Phase 3 randomized,placebo-controlled, double-blind trial, is planned to enroll approximately 300women with recurrent stable angina pectoris who are not candidates forrevascularization and who are receiving optimal drug therapy. The primaryendpoint is the improvement in time to onset of electrocardiogram changesdiagnostic of myocardial ischemia during exercise treadmill testing at sixmonths following administration. The secondary endpoints are improvement inmyocardial blood flow within the affected heart muscle measured by adenosineSPECT imaging, as well as improvements in other measures of angina. The AWAREstudy is expected to include up to 50 U.S. clinical centers. Enrollmentcriteria, participating sites and other information can be found athttp://www.clinicaltrials.gov/ct/show/NCT00438867 and at Cardium's website athttp://www.cardiumthx.com/flash/aware.html.
Advertisement
Currently, there are 49 participating AWARE sites in 32 states across thenation, including: Alabama (University of Alabama, Birmingham); Arizona(Banner Baywood Heart Hospital and Medical Center, Mesa; Southwest Heart,Tucson); California (Cardiovascular Medical Group of Southern CA, BeverlyHills; Cedars-Sinai Medical Center, Los Angeles; LA Cardiology Associates, LosAngeles; Mission Internal Medical Group, Mission Viejo; UCSD Medical Center,San Diego); Colorado (Aurora Denver Cardiology Associates, Aurora; SouthDenver Cardiology Associates, Littleton); District of Columbia (CardiovascularResearch Institute, Washington); Florida (Florida Hospital, Orlando;University of Florida, Gainesville); Georgia (St. Joseph's Research Institute,Atlanta); Idaho (St. Luke's Idaho Cardiology Associates, Boise); Illinois (FoxValley Cardiovascular Consultants, Aurora; Midwest Heart Foundation, Lombard);Indiana (Northern Indiana Research Alliance, Fort Wayne; The Care Group, LLC,Indianapolis); Kentucky (CardioVascular Associates, Louisville); Massachusetts(Massachusetts General Hospital, Boston); Maine (Maine Medical Center,Portland); Michigan (William Beaumont Hospital, Royal Oak); Minnesota(Minneapolis Heart Institute, Minneapolis; St. Mary's Duluth Clinic, Duluth);Missouri (St. Anthony's Medical Center, St. Louis; St. Lukes Hospital, KansasCity); Nebraska (BryanLGH Heart Institute, Lincoln; The Cardiac Center ofCreighton University, Omaha); New Jersey (The Valley Hospital, Ridgewood); NewYork (Lenox Hill Heart & Vascular Institute, New York; University of RochesterMedical Center, Rochester); North Carolina (Duke University Medical Center,Durham); Ohio (The Lindner Clinical Trial Center, Cincinnati; North Ohio HeartCenter, Elria); Oklahoma (Oklahoma Cardiovascular Research Group, Inc.,Oklahoma City); Oregon (Providence Heart & Vascular Institute, Portland);Pennsylvania (Geisinger Clinic, Danville; Heritage Cardiology Associates, CampHill); Rhode Island (The Miriam Hospital, Providence); Tennessee (MeharryMedical College, Nashville; The Stern Cardiovascular Center, Germantown);Texas (Baylor University Medical Center, Dallas; Baylor College of Medicine,Houston; Cardiovascular Associates of
